Brief: NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

Neurosense Therapeutics

07/05/2024 14:19

May 7 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE THERAPEUTICS LTD: ANNOUNCES NEW ANALYSES FROM
ITS
PHASE 2B PARADIGM CLINICAL TRIAL
    * NEUROSENSE THERAPEUTICS LTD: PRIMEC SLOWED DISEASE
PROGRESSION
BY 43% (P=0.02) IN PRE-SPECIFIED HIGH-RISK ALS PATIENTS
    * NEUROSENSE THERAPEUTICS LTD: CONSISTENT DATA ACROSS
SUBGROUPS
UNDERSCORE POTENTIAL OF PRIMEC TO REDEFINE ALS TREATMENT
PARADIGM

Source text for Eikon:  ID:nPn51kcxba 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))